Drug Profile
Research programme: diabetic eye disease therapeutics - Oxurion/Carisma Therapeutics
Alternative Names: TG-931Latest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator ThromboGenics
- Developer Carisma Therapeutics; Oxurion
- Class Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic macular oedema
Most Recent Events
- 07 Mar 2023 Sesen Bio has merged with Carisma Therapeutics to form Carisma Therapeutics
- 10 Sep 2018 Thrombogenics is now called Oxurion
- 28 Jul 2018 No recent reports of development identified for research development in Diabetic-macular-oedema in Belgium